{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-23-000008","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.473412+00:00","generated_at":"2026-06-18T10:38:25.218396+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zymeworks reports FY 2022 net income $124.3M vs loss; $492.2M cash; Jazz deal $375M upfront","bullets":["Revenue $412.5M (FY22) vs $26.7M (FY21) driven by $375M upfront from Jazz collaboration.","Net income $124.3M ($1.90 diluted EPS) vs net loss $211.8M in prior year; cash $492.2M through 2026.","Jazz deal total potential $1.76B; tiered royalties 10-20% on Jazz net sales if approved.","Zanidatamab: Phase 2 BTC cORR 41.3%, median DOR 12.9 months; GEA 84% OS at 18mo.","2023 net cash burn guidance $90-120M incl. $15M capex; zanidatamab zovodotin Phase 2 studies start 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-23-000008","json":"https://secwatch.observer/filing/0001937653-23-000008.json","markdown":"https://secwatch.observer/filing/0001937653-23-000008.md","text":"https://secwatch.observer/filing/0001937653-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000008/0001937653-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000008/zyme-20230307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T10:38:25.218396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c224e4bff927f771f6606838581a847dabc1251","claim":"Zymeworks Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $412.5 million, net income $124.3 million ($1.90 per fully diluted share), EPS $1.90 per fully diluted share.","evidence_excerpt":"Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results • 2022 was a year of transformation and change: ◦ reported $412.5 million in total revenue for the year ended December 31, 2022; ◦ reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000008/0001937653-23-000008-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$412.5 million"},{"label":"Net income","value":"$124.3 million ($1.90 per fully diluted share)"},{"label":"EPS","value":"$1.90 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}